💰 German cancer specialist Catalym GmbH has raised $150m to finance proof-of-concept studies.
🔬 The aim is to demonstrate the efficacy, safety, and licensing potential of Visugromab plus Nivolumab in solid tumors.
💉 CatalYm GmbH plans to start Phase IIb trials in 2025.
🧪 Visugromab is a humanized monoclonal antibody designed to neutralize the tumor’s own Growth Differentiation Factor-15 (GDF-15).
💼 The financing round was led by Canaan Partners and Bioqube Ventures, and supported by other investors.
🔬 The aim is to demonstrate the efficacy, safety, and licensing potential of Visugromab plus Nivolumab in solid tumors.
💉 CatalYm GmbH plans to start Phase IIb trials in 2025.
🧪 Visugromab is a humanized monoclonal antibody designed to neutralize the tumor’s own Growth Differentiation Factor-15 (GDF-15).
💼 The financing round was led by Canaan Partners and Bioqube Ventures, and supported by other investors.
📢 Catalym Raises $150m to Revolutionize Cancer Treatment
Introduction:
German cancer specialist Catalym GmbH has raised US$150m to finance proof-of-concept studies.
Main points:
- The funding will be used to expand the development of Visugromab in randomised Phase IIb trials in stratified checkpoint-naïve first- and second-line treatments.
- Visugromab is a humanised monoclonal antibody designed to neutralise the tumour’s own Growth Differentiation Factor-15 (GDF-15), which is a key mediator of immune resistance to cancer therapeutics.
- The financing round was led by Canaan Partners and Bioqube Ventures and supported by Forbion’s Growth Opportunities Fund, Omega Funds, Gilde Healthcare, and existing investors.
- Visugromab has shown anti-tumour activity in combination with checkpoint inhibitors and has induced complete tumour remission in some patients.
- The funds will also be used to conduct Phase IIb trials in the indications of NSCLC, UC, HCC, and bladder cancer.
Conclusion:
The funding will enable Catalym to further develop Visugromab and demonstrate its efficacy, safety, and licensing potential in Phase IIb trials. If successful, Visugromab could be a promising treatment option for various types of cancer.
